Mild cognitive impairment and progression to dementia of Alzheimer’s disease

Ana Beatriz Quintes Steiner*, Alessandro Ferrari Jacinto2, Vânia Ferreira de Sá Mayoral3, Sonia Maria Dozzi Brucki4, Vanessa de Albuquerque Citero5

1 MD, Psychiatrist, Psychogeriatrist, MSc Student, Psychiatry Department, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil
2 MD, PhD, Geriatrist, Assistant Professor of Geriatrics, Department of Internal Medicine, Faculdade de Medicina de Botucatu (FMB), Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp), Botucatu, SP, Brazil
3 MD, Geriatrician, MSc in Collective Health, FMB-Unesp, Botucatu, SP, Brazil
4 MD, Neurologist. MSc and PhD in Neurology, Unifesp. Post-Doctoral degree from Universidade de São Paulo (USP). Preceptor of the Neurology Residency Program at Hospital Santa Marcelina. Assisting Physician of the Grupo de Neurologia Cognitiva e do Comportamento e do Centro de Referência em Distúrbios Cognitivos (Ceredic), USP, São Paulo, SP, Brazil
5 MD, Psychiatrist, Associate Professor of the Psychiatry Department, EPM-Unifesp, São Paulo, SP, Brazil

SUMMARY

The increase in life expectancy in the Brazilian population raises questions about the preparation of the public health system in identifying elderly patients with signs of cognitive impairment. Currently, as a consequence of the long duration of preclinical phase of Alzheimer’s disease, efforts of early detection have been emphasized. Clinical dementia presents an important impact on the individual’s caregivers, family, society and economy. Identifying individuals who already have some cognitive impairment, despite remaining functional, as well as analyzing associated comorbidities, constitutes an opportunity to analyze possibilities for future interventions. Dementias are clinical conditions that impose a burden on the health system with its high costs, whereas the identification of individuals with cognitive impairment without dementia can aid patients and their families to plan the future and mitigate costs. This narrative revision can provide general practitioners with more information on the subject.

Keywords: elderly, cognitive deficits, mild cognitive impairment, general practice, Alzheimer’s disease, diagnosis.

INTRODUCTION

In the last decades, Brazil has undergone rapid demographic transition with an increase in the population of elderly. The Brazilian life expectancy has reached 73 years and, currently, the elderly represent approximately 10% of the general population. In 2030, they will be 36%.1,2

Along with the aging of the global population, there is an increase in the incidence and prevalence of diseases associated with senility including mild cognitive impairment (MCI) or, according to DSM-5, mild neurocognitive disorder.3 Subjects aged 60 years or older with subjective cognitive complaints corroborated by an informant show an increased conversion rate to MCI or to dementia. The risk of elderly individuals with subjective cognitive complaints to progress to MCI or dementia is 1.5 to 3 higher than in those without it.3 According to Petersen et al.4 the annual conversion rate of amnestic-type MCI to clinical dementia ranges from 10 to 15%.

The term “mild cognitive impairment” was first suggested in 1980 by Reisberg et al.5 The first paper on MCI was published in 1994 by Petersen;6 but only in 1999 Petersen et al.6 further developed the concept by proposing criteria based on an observational study on ageing. The concept of MCI defines an early but abnormal stage of cognitive harm, no longer considered a normal part of aging, and therefore a diagnostic entity and pathological condition. The initial criteria were: a) subjective impairment of the memory, preferentially confirmed by an informant; b) objective impairment of the memory compared with a group paired by age and education level (below 1.5 standard deviations from the mean); c) normal global cognitive functioning; d) independence in daily life activities; and e) absence of dementia. This concept is based on the observation that Alzheimer’s disease (AD) progresses insidiously, usually initiating with a memory deficit that is well characterized, and may allow the diagnosis of AD in the phase of pre-dementia.6
At a Key Symposium held in Stockholm in the year 2003, MCI was defined as a heterogeneous entity divided into three categories: amnestic MCI with greater risk of AD; MCI of multiple cognitive domains; and MCI with impairment of a single cognitive function different from memory. Main diagnostic points of MCI were redefined: the individual being neither normal nor demented; evidence of cognitive decline measured objectively or based on subjective perception combined with objective cognitive impairment; preservation of basic living and complex instrumental activities or minimally compromised. A task force of American authorities, led by the National Institute of Aging and the Alzheimer’s Association, proposed a review of the criteria used for the classification of MCI in 2011. Despite the basic clinical criteria being similar to those for MCI diagnosis, this review opened the focus on the probable etiological mechanisms that lead to cognitive impairment, with emphasis on early diagnosis of AD, via the utilization of biomarkers.

The term “mild cognitive disorder” was included in the International Classification of Diseases (ICD) to be applied to patients that presented a decline in cognitive performance, usually accompanied by abnormalities in objective tests for cognitive functions, but not sufficiently to fulfill the diagnostic criteria of dementia.

**Epidemiology**

The first population-based study on the prevalence of MCI and its subtypes (Figure 1) was based on a cardiovascular health study. The researchers applied the criteria for MCI retrospectively in a cohort and found a prevalence of 22%, of which 6% referred to the amnestic subtype and 16% to multiple domains in patients aged 65 years or older. Other studies demonstrated an incidence rate from 1 to 6% per year and a prevalence of 3 to 22%. The prevalence and incidence of MCI found in Brazil was similar to rates observed in other countries. In a riverside-dwelling population with low education and practically no vascular risk factors, MCI prevalence was 7.7%. A systematic review and meta-analysis on the prevalence of dementia among individuals aged 60 years or older found a narrow range of 5-7% in most world regions, with a higher prevalence in Latin America (8.5%), and a distinctively lower prevalence in the four sub-Saharan African regions (2-4%). In this study, 35.6 million people lived with dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. Yet, in 2010, 58% of all people with dementia lived in countries with low or middle incomes, with this proportion expected to rise to 63% in 2030 and 71% in 2050.

**Progression to AD (Figure 2)**

Several authors observed an increased rate of progression toward dementia in patients with MCI. However, studies have not been replicated by other researchers. One explanation for this fact may arise from the observation that memory complaints appear to have little correlation with the performance of individuals on objective cognitive tests.

On the other hand, longitudinal studies revealed that elderly individuals with recent complaints of impaired memory performed worse in memory tests than those who had not had such a complaint in one year of follow-up. They suggest that memory complaints from the elderly must be taken even more seriously when accompanied by objective signals of cognitive deterioration. Despite some discrepancies among studies, the researchers agree that individuals diagnosed with MCI develop dementia at a faster rate than the rest of the population.

**Evaluation of Memory Problems**

The initial evaluation must rely on careful obtaining of patient history and of memory complaint, always comparing to previous functional state of cognitive complaint, establishing a chronology for the initiation of symptoms, as well as habits and comorbidities; investigation of mood symptoms and behavioral alterations. Questions on dietary and sleep habits must be posed. Detailed neurological and general physical exam must be carried out, with thorough observation of gait and verification of motor signals (alterations of reflexes, rigidity, bradykinesia, tremor, slowness). The laboratory exams that must be performed to rule out reversible dementia syndromes include:

- Thyroid hormone tests to investigate underactive thyroid.
- Vitamin B12 blood test to check vitamin deficiency.
- Complete blood count to investigate infections.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) blood tests that check liver function.
- Chemistry screening to check the level of electrolytes in the blood and to check kidney function.
- Glucose test to check the level of sugar in the blood.
- VDRL and HIV.
- Erythrocyte sedimentation rate, a blood test that investigates signs of inflammation in the body.
- Toxicology screening, examining blood and urine.
- Antinuclear antibodies, a blood test used to diagnose autoimmune diseases.
- Investigation of heavy metals in the blood, such as a lead test.
- A lumbar puncture to test for certain proteins in the spinal fluid.
Mild cognitive impairment

- Cognitive complaint
  - Not normal for age
  - Not demented
  - Cognitive decline
  - Essentially normal functional activities

MCI

Memory impaired?

- Amnestic MCI
  - Memory impairment only?
    - Yes
      - Amnestic MCI Single Domain
    - No
      - Amnestic MCI Multiple Domains
- Non-amnestic MCI
  - Single non-memory cognitive domain impaired?
    - Yes
      - Non-amnestic MCI Single Domain
    - No
      - Non-amnestic MCI Multiple Domain

**FIGURE 1** Current algorithm used to classify the subtypes of mild cognitive impairment (MCI).

Source: Petersen R. 13

**FIGURE 2** Charting the Course from Healthy Ageing to AD.

MCI: mild cognitive impairment; AD: Alzheimer's disease.

Source: National Institute On Aging - NIH.
Neuroimaging exams must be requested, including CT or MRI scans, not only to verify the limbic structures but also to rule out other diseases, particularly vascular cognitive impairment.\textsuperscript{34}

Screening tests such as the mini-exam of the mental state,\textsuperscript{35} clock-drawing test, verbal fluency and a questionnaire on instrumental and basic daily life activities, as well as the geriatric depression scale (GDS) questionnaire, must be applied.\textsuperscript{36,37}

**Neuropsychological testing**
Longitudinal studies investigating the usefulness of neuropsychological tests to identify subjects at high risk of developing dementia reported that, by measuring recall, delayed recall, verbal fluency and visual-motor skill, they were able to identify 85% of the individuals that developed dementia and 95% of those that remained stable, in four years of accompaniment.\textsuperscript{21} The results suggest that individuals with increased risk of developing dementia, or in a preclinical state of AD, can be identified by neuropsychological tests, which evaluate mainly memory (measures of late evocation) and other cognitive functions, such as attention, language and thought.\textsuperscript{23} The standardized application of tests to elderly individuals with cognitive complaints is a manner of rendering the concept of cognitive impairment both valid and reliable.\textsuperscript{38}

**Neuroimaging**
In the initial stages of the disease, cranial MRI might not present abnormalities. In some cases, a SPECT or PET scan can be considered.\textsuperscript{30} In SPECT a decline in blood flow is noted whereas in PET a reduction of glucose utilization is observed. PIB and FDG PET are employed in some research studies to compare controls with patients suffering from AD and MCI.\textsuperscript{39}

**Treatment**
Currently, there is no evidence for the utilization of drugs for the treatment of individuals with MCI.\textsuperscript{40} Nonetheless, several clinical trials have been conducted in an attempt to slow down the appearance of dementia.\textsuperscript{41} There was a large clinical trial involving 70 medical centers in North America.\textsuperscript{42} The study was randomized, double-blind and placebo-controlled and aimed to verify the safety and efficacy of vitamin E (2,000 IU per day) and donepezil (10 mg per day). A decrease, although not significant, was noted in the conversion rate of MCI to AD from 45 to 30% in a three-year period. Among 769 randomized individuals, the annual conversion rate of MCI to AD was approximately 16%. Donepezil reduced the risk of AD in the first 12 months of the trial, but there was no drop in the progression to AD in 36 months. Vitamin E had no therapeutic effect.\textsuperscript{43}

**Conclusion**
Aging of the population is making the cases of chronic degenerative diseases more frequent, including AD. In MCI, a loss of memory for recent facts with relative preservation of functionality is observed. A general practitioner must know that individuals with MCI constitute a group of great risk for AD. Early identification of individuals in the beginning of clinical dementia provides a possibility of intervening in the progression of the disease and providing support to patients and their family members. Upon encountering elderly patients with memory complaints, the physician must perform a detailed anamnesis and complete physical exam, ruling out reversible causes of cognitive alterations. Mood symptoms such as depression and anxiety, if identified, need to be treated. Laboratory exams must include a complete blood count, fasting blood glucose, electrolytes, renal, liver and thyroidal function, lipidogram, folic acid and vitamin B12. An imaging exam such as cranial CT or MR should also be performed. Cognitive testing must include a mini-exam of the mental state (mini-mental), clock-drawing test and verbal fluency for fruits and animals. The Brazilian Public Health System (SUS, in the Portuguese acronym) is responsible for a great portion of patient healthcare in the country. The Family Health Team of Basic Health Units must serve as both the first contact and the longitudinal contact with SUS users, enabling the recognition of the patients’ cognitive impairment and potential progression to AD.

**Resumo**
Comprometimento cognitivo leve e progressão para a demência da doença de Alzheimer

O aumento da expectativa de vida da população brasileira faz surgir questões sobre o preparo do sistema de saúde pública na identificação de pacientes idosos com sinais de alteração cognitiva. Atualmente, como consequência da longa duração da fase pré-clínica da doença de Alzheimer (DA), existe maior ênfase sobre a detecção precoce. A demência apresenta um importante impacto sobre a família, os cuidadores, a sociedade e a economia. Identificar indivíduos que já apresentam algum comprometimento cognitivo, embora eles mantenham a funcionalidade, bem como analisar as comorbidades associadas constituem oportunidades para direcionar futuras intervenções. Depois das doenças que impõem sobrecarga ao sistema
público de saúde, com altos custos. A identificação de indivíduos com alteração cognitiva sem demência pode adicionar planejamentos futuros para o próprio doente, da sua família e dos cuidadores, resultando em menor sobrecarga física e emocional para todos os envolvidos. Esta revisão narrativa tem como objetivo ajudar os clínicos gerais a atuar na detecção dos idosos que se encontram em risco de desenvolver demência.

**Palavras-chave:** idoso, déficit cognitivo, comprometimento cognitivo leve, clínico geral, doença de Alzheimer, diagnóstico.

**Referências**